Translate this page into:
ORIGINAL ARTICLE: Neuroendocrine Tumors
doi:
10.4103/sajc.sajc_176_17
Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience
1
Department of Medical Oncology Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
2
Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
*Corresponding author: Dr. Abhishek Anand. drabhishek2508@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Background: Neuroendocrine carcinoma (NEC) is a rare tumor arising from the diffuse neuroendocrine system. Most of these present in the advanced stage and palliative chemotherapy remains the only option. The prognosis remains poor with the standard chemotherapy regimen of platinum and etoposide (EP) providing modest survival benefit. Methods: The study was done for 3 years at a tertiary cancer center in South India. Patients with a diagnosis of metastatic NEC were analyzed for clinical and pathological characteristics. The treatment outcomes and prognostic factors were evaluated using appropriate statistical test. Results: A total of 114 patients of metastatic NEC satisfied the inclusion criteria and were analyzed. Gastrointestinal including hepatobiliary tract (33%) was the most common site of primary disease followed by lung (26%), genitourinary (15%), head and neck (14%), and unknown primary (9%). On analysis of pattern of metastasis, liver (65%) was the most common site followed by bone (54%) and lung (42%). The median overall survival was 11 months with a statistically significant difference between pulmonary and extrapulmonary disease (8 vs. 13 months; P = 0.003). Ki67% value was strongly associated with prognosis (hazard ratio 0.517, 95% confidence interval; 0.318–0.840, P = 0.008) whereas age, sex, and lactate dehydrogenase level did not show any relation with survival. Conclusion: The outcome of advanced NEC with standard chemotherapy remains poor. Larger studies with other therapeutic and novel agents are warranted to improve the treatment outcomes.
Keywords
References
- Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010;21 Suppl 7:vii65-71.
- Rekhtman N. Neuroendocrine tumors of the lung: An update. Arch Pathol Lab Med 2010;134:1628-38.
- Bertino EM, Confer PD, Colonna JE, Ross P, Otterson GA. Pulmonary neuroendocrine/carcinoid tumors: A review article. Cancer 2009;115:4434-41.
- Modlin IM, Shapiro MD, Kidd M. Siegfried oberndorfer: Origins and perspectives of carcinoid tumors. Hum Pathol 2004;35:1440-51.
- Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80 Suppl 1:3-7.
- Bosman TF, Carneiro F, Hruban R. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press; 2010.
- Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988;109:364-71.
- Pelley RJ, Bukowski RM. Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol 1997;9:68-74.
- Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
- Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T,et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
- Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT,et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75.
- Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R,et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
- Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
- Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group,et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern cooperative oncology group study E1281. J Clin Oncol 2005;23:4897-904.
- Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE,et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
- Pape UF, Anlauf M, Pavel M. Neuroendokrine Neoplasien des gastroenteropankreatischen Systems. Gastroenterologie up2date 2011;7:313–42.
- Terashima T, Morizane C, Hiraoka N, Tsuda H, Tamura T, Shimada Y,et al. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology 2012;96:324-32.
- Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K,et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014;105:1176-81.
- Fujiwara Y, Sekine I, Tsuta K, Ohe Y, Kunitoh H, Yamamoto N,et al. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol 2007;37:482-6.
- Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK,et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer 2012;77:365-70.
- Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H,et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: The GFPC 0302 study. Ann Oncol 2013;24:1548-52.
- Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M,et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: A multicenter phase II study. J Thorac Oncol 2013;8:980-4.
- Yoshida H, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N,et al. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol 2011;41:897-901.
- Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K,et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117:4617-22.
- Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P,et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 2013;24:152-60.
- Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M,et al. FOLFIRI regimen: An effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012;19:751-7.
- Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U,et al. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ScientificWorldJournal 2012;2012:170496.
- Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015;22:289-98. doi:10.1530/ERC-15-0075